Ocular olopatadine administration provides adjuvant effects on allergic nasal symptoms

Article

Analyses of data from two hybrid environmental studies evaluating 0.2% olopatadine HCl ophthalmic solution QD for the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis show that patients derive improvement in the frequency or severity of their nasal symptoms as a simultaneous benefit with relief of ocular allergy.

Key Points

The two trials, a spring study with a 10-week duration and the other conducted over 12 weeks in the fall allergy season, had a randomized, placebo-controlled, double-masked design with a combined enrollment of 500 patients.

Tracking nasal symptoms

The use of any other topical ocular medications or new systemic medications was not allowed. More than 90% of enrolled patients had a history of rhinoconjunctivitis.

Frequency of sneezing and runny nose were significantly lower in the spring study among patients using QD olopatadine 0.2% compared with controls. In the spring study, the frequency of runny nose, as well as the severity of sneezing, itchy nose, and runny nose, all were significantly lower in the olopatidine-treated patients.

There was a marginally non-significant difference in the frequency of runny nose favoring the olopatadine group, reported Dr. Abelson, who is lead author of the published study results [Curr Med Res Opin 2005;21:5:683-691], associate clinical professor of ophthalmology, Harvard Medical School, and senior clinical scientist, Schepens Eye Research Institute, Boston.

"These two environmental studies of [QD] olopatadine 0.2% were designed primarily to investigate the safety and efficacy of olopatadine in treating ocular signs and symptoms in patients with allergic conjunctivitis or allergic rhinoconjunctivitis and not to assess its effects on nasal symptoms," he said.

"However, they were well-designed, rigorously conducted clinical trials representing a large population of patients primarily with rhinoconjunctivitis from across the nation and treated during two distinct allergy seasons," Dr. Abelson said.

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.